BIO Announces Selection of 2009 Presenting Companies for 8th Annual BIO Investor Forum
The BIO Investor Forum will feature over 110 company presentations from select late-stage private and emerging public biotech companies. Companies were chosen through a competitive screening process with input by an advisory committee comprised of members from top-tier firms focused on investing and banking in the life sciences industry. The advisory committee includes:
· Benjamin R. Bowen, Ph.D., Rodman & Renshaw, LLC
· Howard Furst, M.D., Deerfield Management
· John R. Leone, Paul Capital
· Graeme Martin, Ph.D., Takeda Research Investments, Inc.
· Evan McCulloch, CFA, Franklin Templeton Investments
· Oleg Nodelman, Biotechnology Value Fund, LP
· Heather Preston, M.D., TPG Biotech
· Bryan E. Roberts, Ph.D., Venrock
· Mark Schoenebaum, M.D., Deutsche Bank AG
· Chris Swindle, Wedbush PacGrow Life Sciences
· Paul Wagner, Ph.D., CFA, RCM Capital Management, LLC
“The BIO Investor Forum will feature senior management from biotech companies that are poised for leadership status in highly competitive areas of therapeutic innovation,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “The companies selected to speak in 2009 are creating value through development-stage programs with near-term clinical catalysts. `These are the companies that will help drive the investment and deal making in the life sciences sector and global innovation in healthcare.”
The following companies will present at the 8th Annual BIO Investor Forum:
Anadys Pharmaceuticals Inc. (ANDS)
BioSante Pharmaceuticals, Inc. (BPAX)
Cyclacel Pharmaceuticals Inc. (CYCC)
ExonHit Therapeutics S.A. (ALEHT)
ImmunoVaccine Technologies Inc.
LigoCyte Pharmaceuticals, Inc.
Newron Pharmaceuticals S.p.A. (NWRN)
NovaBay Pharmaceuticals Inc. (NBY)
Novelos Therapeutics Inc. (NVLT)
Oncolytics Biotech Inc. (ONCY)
Presidio Pharmaceuticals, Inc.
Raptor Pharmaceuticals Corp. (RPTP)
Resolvyx Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. (SOMX)
Supernus Pharmaceuticals, Inc.
Transcept Pharmaceuticals, Inc. (TSPT)
Trubion Pharmaceuticals Inc. (TRBN)
WaferGen Bio-Systems Inc. (WGBS)
The BIO Investor Forum will also host panels for industry leaders to weigh strategies for efficient product development, evaluating therapeutic investment and accessing capital and resources. Highlights for this year’s conference include plenary sessions on sustaining biotech innovation in light of healthcare reform, as well as forecasting key industry and investment catalysts for 2010. Therapeutic workshops will address areas of dynamic pipeline growth including prostate cancer, influenza, autoimmune disease and personalized medicine; and this year’s business roundtables will offer the buyer’s perspective on today’s IPO candidates and prospects, the insider’s view on designing clinical trials that increase deal value, and new deal structures designed to reduce M&A risk.
The BIO Investor Forum is a national investor conference featuring leading private and emerging public companies. The meeting attracts sophisticated healthcare venture capital and public market investors and research analysts. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and biotechnology companies.
To learn more about the BIO Investor Forum, including registration and program information, please visit http://investorforum.bio.org/. Registration is complimentary for qualified investors.
BIO Investor Forum
October 28-29, 2009
San Francisco, CA
Advanced Business Development Course
October 30, 2009
Vienna, Austria
BIO Europe International Partnering Conference
November 2-4, 2009
Vienna, Austria
Pacific Rim Summit on Industrial Biotechnology and Bioenergy
November 8-11, 2009
Honolulu, HI
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
###